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Abstract 
Hydroxychloroquine (HCQ) is in critical shortage in the U.S. because of its use off-label for 
treatment of viral pneumonia secondary to the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). A repeated cross-sectional study of the Medical Expenditure Panel Survey was 
used to describe trends in HCQ medication use over time to estimate the impact of HCQ 
shortage. As of 2017, approximately 81% of over 1 million individuals prescribed HCQ use this 
medication longitudinally. Critical drug shortages related to off-label use for SARS-COV-2 
infection could impact hundreds of thousands of individuals who use the medication for 
rheumatological diseases.  
 





This article is a preprint and has not been peer reviewed. It reports new medical research or thought that has yet to 
be evaluated and so should not be used to guide clinical practice. Copyright © 2020 by Joshua D. Niforatos, MD, 
MTS; Michael E. Johansen, MD, MS. Posted on Annals of Family Medicine COVID-19 Collection, courtesy of Joshua 
D. Niforatos. 
Introduction 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak was declared a 
pandemic on March 11, 2020.1 To-date, no randomized trial has robustly demonstrated treatment 
efficacy for viral pneumonia secondary to SARS-CoV-2. Nevertheless, the antimalarial  
hydroxychloroquine (HCQ) is currently being used ubiquitously in the U.S. despite inconclusive 
evidence from a few small, poorly controlled or non-randomized trials.2 Shortly after uptake of 
HCQ in the pandemic, the Food and Drug Administration (FDA) announced critical shortages of 
this medication.3 Given the important use of HCQ for rheumatologic disorders, such as systemic 
lupus erythematosus and rheumatoid arthritis,4 we sought to investigate the use of HCQ in the 
U.S. to determine the potential impact of critical shortages of HCQ will have on the non-
pandemic population.  
 
Methods 
A repeated cross-sectional study of the Medical Expenditure Panel Survey (MEPS) was used to 
describe trends in HCQ medication use over time. Sponsored by the Agency of Healthcare 
Research and Quality (AHRQ), MEPS is representative of the noninstitutionalized population of 
the United States. Each year of the survey comprises two overlapping cohorts, which are 
interviewed five times over the 2 years. The survey includes information regarding 
demographics and prescription medication utilization. All adult individuals included in the 
survey between 2002-2017 were included in the analysis. Survey years were grouped into two 
year groups. HCQ was identified through the prescription medication name. The survey uses 
numerous methods to achieve accurate reporting of prescription medications including 
contacting pharmacies.5 Previous studies have validated the accuracy of chronic medication 
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reporting in MEPS.6 An individual was identified as a medication user if he or she had any use of 
the medication during a given year.  
 
Complex survey weights were used in all analyses to make these analyses representative of the 
non-institutionalized population of the United States. 95% confidence intervals are reported in 
the figures. The OhioHealth Institutional Review Board ruled the study exempt. All analyses 
used STATA 15 (College Station, Tx).  
 
Result 
Between 2002-2003 to 2016-2017, the use of HCQ increased 363.6% from 226,242 individuals 
per year (95% CI, 159,425-293,060) to 1,048,901 individuals per year (95% CI, 853,550-
1,244,251), respectively. Figure 1 provides a graphical depiction of HCQ prescription fills over 
time. Notably, the proportion of patients with greater than 1 prescription fill ranged from a low 




Between 2002 to 2016 the use of HCQ in the U.S. population increased substantially. 
Importantly, over 80 percent of patients prescribed HCQ use this prescription more than once in 
any given two-year period. These data suggest that the vast majority of HCQ use in the U.S. are 
by patients who use this drug longitudinally.  
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This study was limited by self-reported medication use, possible under-reporting of medications 
use, and an inability to determine the precise reason for HCQ prescription fills.  
 
According to the FDA’s list of drug shortages, nine pharmaceutical manufacturers have provided 
updates regarding HCQ shortages.6 Most reasons are secondary to limited supply in the setting of 
significantly increased demand for this medication. Companies like Amneal Pharmaceuticals and 
Novartis have announced plans to increase production of HCQ to meet national demand during 
the pandemic.6 Regardless, critical drug shortages for the foreseeable future related to off-label 
use for SARS-COV-2 infection could impact hundreds of thousands of individuals who use the 
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Figure 1. Hydroxychloroquine Use in the United States, 2002-2016 
 
Rate of hydroxychloroquine use with any fill and > 1 fill in both years across the United States 
population.  
 
